Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on July 2, 2025
NutriSelect and Zupe Partner to Advance Global Wellness Technology and Consumer Empowerment
EIN Presswire
·
July 2, 2025
Two innovative platforms join forces to bring AI-powered supplement intelligence and community-based wellness to international audiences. CLEARWATER, FL, UNITED STATES, July 2, 2025 /EINPresswire.com/ -- NutriSelect.ai, Inc., a pioneering health tech …
Senior Care Expert Launches Hometown Senior Placement in Florida
EIN Presswire
·
July 2, 2025
Elizabeth Brennen, a second-generation registered nurse, is proud to introduce Hometown Senior Placement, specializing in dementia and geriatric care. PALM BEACH GARDENS, FL, UNITED STATES, July 2, 2025 /EINPresswire.com/ -- Ms. Brennen, a Palm Beach …
Range Impact Announces Expansion of Investment in its Fola Mine Complex with Acquisition of Two Mining Permits and Two Coal Leases
GlobeNewswire
·
July 2, 2025
CLEVELAND, OHIO, July 02, 2025 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming and repurposing distressed coal mines throughout Appalachia, today announced the …
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
July 2, 2025
BOSTON, July 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
July 2, 2025
WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, …
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
July 2, 2025
SAN FRANCISCO, July 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for …
Oragenics Completes Approximately $16.5 Million Offering
GlobeNewswire
·
July 2, 2025
SARASOTA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering intranasal therapeutics for neurological disorders, today announced the successful closing of its previously …
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
GlobeNewswire
·
July 2, 2025
FLORHAM PARK, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced …
Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry
GlobeNewswire
·
July 2, 2025
PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, is proud to announce enrollment of the first patient in the Acclarent AERA Pediatric Registry, a …
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
GlobeNewswire
·
July 2, 2025
GAITHERSBURG, Md., July 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the expansion of its proprietary NARCANDirect® online distribution network to include KLOXXADO® (naloxone HCl) Nasal Spray 8 mg. The platform …
Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market
GlobeNewswire
·
July 2, 2025
PASADENA, CALIF, July 02, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a private placement with accredited investors for the purchase and …
4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
GlobeNewswire
·
July 2, 2025
4FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 2027 4FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre-commercial organization aligns with focused pipeline shift, as announced in January 2025 …
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
·
July 2, 2025
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2025 the Company granted inducement awards to purchase up …
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
GlobeNewswire
·
July 2, 2025
WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of …
Inventiva annonce la publication dans le Journal of Hepatology Reports des résultats du lanifibranor sur les cellules endothéliales sinusoïdales hépatiques chez des patients MASLD/MASH et dans des modèles précliniques de la maladie
GlobeNewswire
·
July 2, 2025
L'analyse des cellules endothéliales sinusoïdales hépatiques (« LSEC ») dans les biopsies de screening et de fin de traitement dans l'étude de Phase 2b NATIVE a mis en évidence une capillarisation des LSEC chez les patients atteints de MASLD, avec une …
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease
GlobeNewswire
·
July 2, 2025
Analysis of liver sinusoidal endothelial cells (“LSEC”) from screening and end of treatment biopsies in the Phase 2b NATIVE study showed evidence of LSEC capillarization in patients without MASH, and a further increased capillarization in patients with …
Phoenix Accident Doctors Unveils a New Way to End Car Accident Pain Permanently Without Surgery
GlobeNewswire
·
July 2, 2025
Phoenix, Arizona, July 02, 2025 (GLOBE NEWSWIRE) -- Dr. Thanh Nguyen of The Accident Doctors AZ has created an innovative platelet treatment that resolves chronic pain with an over 90% success rate by harnessing the body's natural healing abilities. …
New Study: 4 in 5 Americans Have Experienced Heat Exhaustion Symptoms, Ergodyne Finds
GlobeNewswire
·
July 2, 2025
St. Paul, MN, July 02, 2025 (GLOBE NEWSWIRE) -- 4 in 5 Americans have experienced the warning signs of heat exhaustion, according to a new survey for Extreme Heat Month this July from pioneering safety work gear provider Ergodyne. The survey marks the …
Mesa Laboratories, Inc. to Announce First Quarter Results on August 5, 2025
GlobeNewswire
·
July 2, 2025
LAKEWOOD, Colo., July 02, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the first quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern time on Tuesday, August 5, 2025. About …
Emerging Clinical Trial Infrastructure in the MENA Region: A Comprehensive Market Analysis
GlobeNewswire
·
July 2, 2025
Boston, July 02, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Clinical Trial Infrastructure Regional Analysis Market: Middle East and North Africa” is expected to reach $1.3 billion by the end of 2029 at a compound annual …